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Introduction {#sec0005}
============

Endemic to Southeast Asia, East Asia and China, *Talaromyces marneffei* is a dimorphic fungus capable of causing systemic fungal infections in immunocompromised patients ([@bib0060]). Since its discovery in the 1950s, the majority of cases have been documented in HIV patients with low CD4 counts. In northern Thailand, *T. marneffei* is the fourth most prevalent opportunistic infection in this population ([@bib0010]). Clinical manifestations include fever, malaise, lymphadenopathy, cough, and hepatosplenomegaly ([@bib0070]). While the frequency of *T. marneffei* infection has decreased with the advent of retroviral therapy, if left untreated the infection frequently leads to respiratory failure with a poor prognosis.

In the U.S. patients with HIV infection usually undergo testing for endemic fungal infections such as *Blastomyces, Histoplasma, Coccidioides and Paracoccidioides.* Indirect serological results help to make faster decisions given that cultures take several days or weeks to grow. Clinical and geographic context plays a particularly important role because some of these tests have been shown to have cross-reactivities. Pulmonary infection either by fungi, bacteria or virus has been observed to cause concomitant hyponatremia, with inappropriate levels of anti-diuretic hormone (SIADH) often found as the underlying etiology. The exact mechanism is not understood but hypoxemia and hypercapnia are thought to play an important role in the pathophysiology ([@bib0040]).

In the following, we describe a *T. marneffei* infection with unusual laboratory and clinical characteristics.

Case {#sec0010}
====

The patient was a 35-year-old male from Thailand who presented with generalized weakness and fever. His past medical history was relevant for HIV infection (since age 21) on HAART (bictegravir, emtricitabine & tenofovir alafenamide). Two weeks prior to his admission, he had travelled to Chicago, Las Vegas and Utah. During this time, he developed a productive cough with blood-tinged sputum, subjective fever, chills, and anorexia with associated weight loss.

On physical exam, he was noted to have multiple erythematous, raised, scaly/crusted lesions on the face, neck and abdomen ([Figure 1](#fig0005){ref-type="fig"} ), as well as concomitant cervical lymphadenopathy. Initial laboratory studies revealed hyponatremia \[Na 121 mmol/L\] and hypochloremia \[88 mmol/L\] with normal creatinine \[0.59 mg/dl\]. Hepatic transaminases and alkaline phosphatase were elevated \[AST 269 U/L, ALT 89U/L, Alk Phos 1209 U/L, Bili 0.9 mg/dl\] and cell count was within normal limits \[WBC 5.7 10^3^/uL, RBC 4.510^3^/uL, Platelets 208 10^3^/uL\]. The patient had received normal saline in the emergency department without improvement in his sodium level. Subsequent tests showed increased urine osmolality \[491 mOsm/Kg\], decreased serum uric acid \[5 mg/dl\] and increased urine sodium \[112 mEq/L\] despite volume replacement and euvolemic clinical status.Figure 1Computed Tomography showing multiple centimeter and sub-centimeter intraparenchymal nodules and perihiliar pulmonar lymphadenopathy.Figure 1

HIV viral load was 3.12 \* 10^6^  copies/mL and CD4 count was 8 cells/μL. Right upper quadrant ultrasound revealed hepatomegaly and a chest x-ray reported bilateral peri-tracheal soft densities up to 3 cm in diameter, interstitial markings, and bilateral pulmonary nodules. Chest CT scan without contrast showed patchy pulmonary densities and multiple peri-hilar nodules ([Figure 2](#fig0010){ref-type="fig"} ). CT scan with contrast of the head and neck did not reveal acute intracranial abnormalities but did show cervical lymphadenopathy. Gram stain smear and culture of the sputum were negative. Respiratory viral panel including influenza, parainfluenza, coronavirus and RSV was negative. Legionella urine antigen was negative. Bacterial blood cultures and gram stain were negative. QuantiFERON gold and three sputum samples for AFB/culture were negative for tuberculosis. Serological testing for *Cryptococci* and *Blastomyces* were negative. However, urine antigen testing for both *Blastomyces* and *Histoplasma* were positive. Finally, a biopsy of one of the cutaneous lesions demonstrated dermal and subcutaneous neutrophil and histiocyte infiltrate with the presence of intracellular yeast, findings which were consistent with T. marneffei.Figure 2Multiple facial erythematous papular lesions.Figure 2

Discussion {#sec0015}
==========

*T. marneffei* infections typically manifest in severely immunocompromised patients. Current guidelines recommend that in HIV patients from endemic countries with a CD4 count \<100 cells/μL, primary preventive therapy with itraconazole should be initiated ([@bib0035]). Clinical manifestations appear to vary depending on the severity and underlying etiology of immune compromise in the patient, differing between HIV vs. non-HIV causes such as malignancies or transplant patients. Fever, splenomegaly, anemia, transaminitis, and absence of leukocytosis seem to be more frequently found in HIV-positive patients ([@bib0030]). In our case, clinical findings included fever, neck lymphadenopathy, and respiratory symptoms. Laboratory work demonstrated transaminitis along with a CD4 count of 8 cells/μL.

An initial laboratory test for endemic fungi can guide initial treatment towards early antifungal medication. However, cross-reactivity between antigens in various fungal infection detection tests is well-documented, and cross reactions between *Histoplasma* and *Blastomyces* antigens are the most common ([@bib0065]). Others have been described, such as that of *Histoplasma* antigen in patients with sporotrichosis ([@bib0005]). In our case, urine antigen testing results for both *Histoplasma* and *Blastomyces* were positive, serum testing was negative.

It is of note that the sensitivities of the *Blastomyces* and *Histoplasma* antigen detection test in urine are approximately 80% and 89% respectively. Specificity is around 90% for both tests, usually having to rule out each other as the main confounder ([@bib0015], [@bib0025]). HIV status can affect tests based on antibody detection. Since the tests used to guide therapy are based on antigen detection, sensitivity is unlikely to be affected by HIV infection. These infections in their disseminated forms will receive amphotericin-B with itraconazole. However, differentiation is important given that blastomycosis is treated for a year versus talaromyces which is treated for 12 weeks ([@bib0055], [@bib0045]).

SIADH is an exclusion diagnosis that requires an extensive work up to rule out other etiologies including adrenal insufficiency, thyroid disease, and volume depletion ([@bib0050]). ADH is produced on the paraventricular thalamic nucleus and thus classically this syndrome is observed after neurological insults that cause an excess in ADH. Nevertheless, it has been observed that respiratory tract infections can cause inadequate ADH secretion and these are the most common infections in HIV patients. Increase in the A-a gradient and hypoxia/hypercapnia-induced ADH secretion are some of the non-osmotic mechanisms thought to trigger elevations in ADH in this population. It has been proposed that hypercapnic acidosis and hypoxemia induce central release of vasopressin through peripheral chemoreceptors and baroreceptors stimulation respectively ([@bib0040], [@bib0020]). Tuberculosis, cryptosporidium, plasmodium infections and *Pneumocystis pneumonia* have been previously reported as pulmonary infections causing SIADH. It is of note that HIV by itself could contribute to SIADH. But the mechanism underlying this infection is usually mediated by HIV induced thyroid and adrenal insufficiency. In our case, the patient had increased urinary sodium, decreased serum osmolality, normal cortisol and TSH levels and absence of neurological affect, leaving the pulmonary fungal infection as one of the explanations for inadequate ADH secretion.

In conclusion, laboratory work up for endemic fungal infection can have false positive results with infections such as Talaromyces. This cross reactivity is especially important when assessing patients from endemic countries. Manifestations of T. marneffei infection are diverse, and disease description is limited due to the small number of cases. A novel manifestation observed in our patient was the presence of SIADH likely secondary to the respiratory Talaromyces infection. To our knowledge, this is the first case reporting systemic mycosis due to Talaromyces marneffei with associated hyponatremia secondary to SIADH and cross-reactivity with *Blastomyces* and *Histoplasma* in urine antigen testing.

Aknowledgement is given to Dr Saad, Peguy who proof read this manuscript.

Consent was obtained from patient for the publication of this manuscript.

Consent was obtained from patient for the publication of this manuscript.

Funding sources {#sec0020}
===============

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest {#sec0025}
====================

The authors declare no conflict of interest.
